Evergreen Theragnostics, Inc.
Evergreen Theragnostics, founded in 2019, is a US-based radiopharmaceutical company consisting of three business units: CDMO, Products, and Discovery. Our CDMO business unit is dedicated to high quality & high reliability manufacturing of radiopharmaceuticals using a variety of isotopes, from early development through commercialization. We offer research and commercial scale, centralized production capacity for therapeutic and long-lived diagnostic products in our brand-new state of the art manufacturing facility in Springfield, NJ. We can also expand operations within our existing walls for project-specific needs or partnership opportunities. Our combination of top industry talent, compliance with global cGMP standards, and strategic facility location uniquely position Evergreen as a premier radiopharmaceutical CDMO partner in North America. The Products business unit develops and commercializes Evergreen-owned assets. A marketing authorization application for the first product, Ga-68 DOTATOC, has been submitted to FDA. Evergreen Discovery is focused on developing novel radiopharmaceuticals for cancer therapy, focusing on unprecedented and first-in-class radiopharmaceuticals.